Abstract
The following text from the first paragraph of the Discussion of this paper is an unattributed quote from a review by Gowans et al. (2004), which was inadvertently not cited in the paper. The authors apologize sincerely for this oversight.
There is therefore a high probability that DCs from HCV carriers that are loaded and matured ex vivo with HCV proteins followed by autologous transfusion will be able to prime naive T-cells and/or stimulate existing HCV-specific cellular immunity. The aim then is to change the equilibrium between the virus and the immune response in patients that will result in viral clearance. In addition, it has been suggested that the number of impaired DCs is small (Sarobe et al., 2002), so autologous transfusion of a large number of HCV antigen-loaded matured DCs may overcome the impairment.